{"id":5106,"date":"2019-04-02T09:56:05","date_gmt":"2019-04-02T14:56:05","guid":{"rendered":"https:\/\/www.appliedpolicy.com\/staging\/7403\/?p=5106"},"modified":"2019-04-10T10:00:13","modified_gmt":"2019-04-10T15:00:13","slug":"louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations","status":"publish","type":"post","link":"https:\/\/www.appliedpolicy.com\/staging\/7403\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\/","title":{"rendered":"Louisiana&#8217;s Innovative Subscription Model Contract to Provide Hepatitis C Drugs to the State&#8217;s Underserved Populations"},"content":{"rendered":"<p>[vc_row full_width=&#8221;stretch_row&#8221; gap=&#8221;35&#8243;][vc_column][vc_column_text]Louisiana took a precedent-setting step last week to confront the costly public health challenges associated with the Hepatitis C virus, (HCV) at the same time embarking on a plan to eventually rid the state of HCV.\u00a0 Health policy experts nationwide are watching the innovative program, anticipating that it could provide a model for states nationwide.<\/p>\n<p>Secretary of the Louisiana Department of Health Dr. Rebekah Gee, speaking at the 2019 conference of the National Quality Forum, announced that the state had signed a partnership with Gilead Sciences to provide medication on a subscription model for HCV treatment of Medicaid and corrections patients, rather than paying prescription by prescription.\u00a0 This will allow state healthcare officials to turn their focus from treatment to prevention, and \u2013 at the same time \u2013 guarantee that payments to Gilead will remain largely the same over the five year period of its contract with the state. By that time, it is anticipated that HCV will have been largely eradicated in Louisiana, ensuring that there will be little or no need for the expensive HCV medication.<\/p>\n<p>The partnership between Gilead and the state of Louisiana was the result of a broad collaboration including the governor of the state, and Sen. Bill Cassidy (R-LA). As part of the process to design the program, the health department sought guidance from CMS on how to design the model so that it would\u00a0not\u00a0require\u00a0a\u00a0waiver\u00a0of the Medicaid best price rule. Louisiana\u2019s subscription model would be the first of its kind and the agreement between the state and the company will need CMS\u2019 approval.<\/p>\n<p>Applied Policy has championed the Louisiana approach, endorsing it in an article in Morning Consult late last <a href=\"https:\/\/morningconsult.com\/opinions\/take-note-washington-louisiana-may-be-something\/,\">year<\/a> and explaining the possible impact on healthcare nationwide more recently in <a href=\"https:\/\/insidehealthpolicy.com\/daily-news\/gilead-subsidiary-wins-louisiana-hep-c-drug-subscription-model-contract\">Inside Health Policy<\/a>. \u00a0We endorse the innovative use of CMS funds to help address the rising cost of health care and, at the same time, deliver superior care to an underserved population.[\/vc_column_text][\/vc_column][\/vc_row][vc_row full_width=&#8221;stretch_row&#8221; gap=&#8221;35&#8243;][vc_column width=&#8221;1\/3&#8243;][vc_custom_heading text=&#8221;Applied Policy in the News&#8221; use_theme_fonts=&#8221;yes&#8221;][vc_column_text]x[\/vc_column_text][\/vc_column][vc_column width=&#8221;1\/3&#8243;][vc_custom_heading text=&#8221;Meet the Team&#8221; use_theme_fonts=&#8221;yes&#8221;][vc_column_text]x[\/vc_column_text][\/vc_column][vc_column width=&#8221;1\/3&#8243;][vc_custom_heading text=&#8221;Philanthropy&#8221; use_theme_fonts=&#8221;yes&#8221;][vc_column_text]x[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>[vc_row full_width=&#8221;stretch_row&#8221; gap=&#8221;35&#8243;][vc_column][vc_column_text]Louisiana took a precedent-setting step last week to confront the costly public health challenges associated with the Hepatitis C virus, (HCV) at the same time embarking on a plan to eventually rid the state of HCV.\u00a0 Health policy experts nationwide are watching the innovative program, anticipating that it could provide a model for [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":5107,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","ap4_related_services":"","footnotes":""},"categories":[503,429,436],"tags":[161,519,518,64,172,520],"class_list":["post-5106","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health-care-spending","category-healthcare-delivery-payment","category-healthcare-policy-development","tag-health-policy","tag-hepatitis-c","tag-louisiana","tag-medicaid","tag-prescription-drug-pricing","tag-subscription-model"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Louisiana&#039;s Innovative Subscription Model Contract to Provide Hepatitis C Drugs to the State&#039;s Underserved Populations - Applied Policy<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/appliedpolicy.com\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Louisiana&#039;s Innovative Subscription Model Contract to Provide Hepatitis C Drugs to the State&#039;s Underserved Populations - Applied Policy\" \/>\n<meta property=\"og:description\" content=\"[vc_row full_width=&#8221;stretch_row&#8221; gap=&#8221;35&#8243;][vc_column][vc_column_text]Louisiana took a precedent-setting step last week to confront the costly public health challenges associated with the Hepatitis C virus, (HCV) at the same time embarking on a plan to eventually rid the state of HCV.\u00a0 Health policy experts nationwide are watching the innovative program, anticipating that it could provide a model for [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/appliedpolicy.com\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\/\" \/>\n<meta property=\"og:site_name\" content=\"Applied Policy\" \/>\n<meta property=\"article:published_time\" content=\"2019-04-02T14:56:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-04-10T15:00:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/appliedpolicy.com\/wp-content\/uploads\/LA.png\" \/>\n\t<meta property=\"og:image:width\" content=\"200\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jim Scott\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jim Scott\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/appliedpolicy.com\\\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/appliedpolicy.com\\\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\\\/\"},\"author\":{\"name\":\"Jim Scott\",\"@id\":\"https:\\\/\\\/appliedpolicy.com\\\/#\\\/schema\\\/person\\\/a200caa45751a466fa9e77c10844020b\"},\"headline\":\"Louisiana&#8217;s Innovative Subscription Model Contract to Provide Hepatitis C Drugs to the State&#8217;s Underserved Populations\",\"datePublished\":\"2019-04-02T14:56:05+00:00\",\"dateModified\":\"2019-04-10T15:00:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/appliedpolicy.com\\\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\\\/\"},\"wordCount\":437,\"image\":{\"@id\":\"https:\\\/\\\/appliedpolicy.com\\\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.appliedpolicy.com\\\/staging\\\/7403\\\/wp-content\\\/uploads\\\/LA.png\",\"keywords\":[\"health policy\",\"hepatitis C\",\"Louisiana\",\"medicaid\",\"Prescription Drug Pricing\",\"subscription model\"],\"articleSection\":[\"Health Care Spending\",\"Healthcare Delivery &amp; Payment\",\"Healthcare Policy Development\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/appliedpolicy.com\\\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\\\/\",\"url\":\"https:\\\/\\\/appliedpolicy.com\\\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\\\/\",\"name\":\"Louisiana's Innovative Subscription Model Contract to Provide Hepatitis C Drugs to the State's Underserved Populations - Applied Policy\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/appliedpolicy.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/appliedpolicy.com\\\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/appliedpolicy.com\\\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.appliedpolicy.com\\\/staging\\\/7403\\\/wp-content\\\/uploads\\\/LA.png\",\"datePublished\":\"2019-04-02T14:56:05+00:00\",\"dateModified\":\"2019-04-10T15:00:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/appliedpolicy.com\\\/#\\\/schema\\\/person\\\/a200caa45751a466fa9e77c10844020b\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/appliedpolicy.com\\\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/appliedpolicy.com\\\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/appliedpolicy.com\\\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.appliedpolicy.com\\\/staging\\\/7403\\\/wp-content\\\/uploads\\\/LA.png\",\"contentUrl\":\"https:\\\/\\\/www.appliedpolicy.com\\\/staging\\\/7403\\\/wp-content\\\/uploads\\\/LA.png\",\"width\":200,\"height\":200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/appliedpolicy.com\\\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/appliedpolicy.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Louisiana&#8217;s Innovative Subscription Model Contract to Provide Hepatitis C Drugs to the State&#8217;s Underserved Populations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/appliedpolicy.com\\\/#website\",\"url\":\"https:\\\/\\\/appliedpolicy.com\\\/\",\"name\":\"Applied Policy\",\"description\":\"Health policy and reimbursement consulting\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/appliedpolicy.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/appliedpolicy.com\\\/#\\\/schema\\\/person\\\/a200caa45751a466fa9e77c10844020b\",\"name\":\"Jim Scott\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.appliedpolicy.com\\\/staging\\\/7403\\\/wp-content\\\/uploads\\\/Scott_Jim-031-300x300.jpg\",\"url\":\"https:\\\/\\\/www.appliedpolicy.com\\\/staging\\\/7403\\\/wp-content\\\/uploads\\\/Scott_Jim-031-300x300.jpg\",\"contentUrl\":\"https:\\\/\\\/www.appliedpolicy.com\\\/staging\\\/7403\\\/wp-content\\\/uploads\\\/Scott_Jim-031-300x300.jpg\",\"caption\":\"Jim Scott\"},\"description\":\"PRESIDENT &amp; CEO\",\"url\":\"https:\\\/\\\/www.appliedpolicy.com\\\/staging\\\/7403\\\/author\\\/jim-scott\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Louisiana's Innovative Subscription Model Contract to Provide Hepatitis C Drugs to the State's Underserved Populations - Applied Policy","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/appliedpolicy.com\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\/","og_locale":"en_US","og_type":"article","og_title":"Louisiana's Innovative Subscription Model Contract to Provide Hepatitis C Drugs to the State's Underserved Populations - Applied Policy","og_description":"[vc_row full_width=&#8221;stretch_row&#8221; gap=&#8221;35&#8243;][vc_column][vc_column_text]Louisiana took a precedent-setting step last week to confront the costly public health challenges associated with the Hepatitis C virus, (HCV) at the same time embarking on a plan to eventually rid the state of HCV.\u00a0 Health policy experts nationwide are watching the innovative program, anticipating that it could provide a model for [&hellip;]","og_url":"https:\/\/appliedpolicy.com\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\/","og_site_name":"Applied Policy","article_published_time":"2019-04-02T14:56:05+00:00","article_modified_time":"2019-04-10T15:00:13+00:00","og_image":[{"width":200,"height":200,"url":"https:\/\/appliedpolicy.com\/wp-content\/uploads\/LA.png","type":"image\/png"}],"author":"Jim Scott","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Jim Scott","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/appliedpolicy.com\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\/#article","isPartOf":{"@id":"https:\/\/appliedpolicy.com\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\/"},"author":{"name":"Jim Scott","@id":"https:\/\/appliedpolicy.com\/#\/schema\/person\/a200caa45751a466fa9e77c10844020b"},"headline":"Louisiana&#8217;s Innovative Subscription Model Contract to Provide Hepatitis C Drugs to the State&#8217;s Underserved Populations","datePublished":"2019-04-02T14:56:05+00:00","dateModified":"2019-04-10T15:00:13+00:00","mainEntityOfPage":{"@id":"https:\/\/appliedpolicy.com\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\/"},"wordCount":437,"image":{"@id":"https:\/\/appliedpolicy.com\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\/#primaryimage"},"thumbnailUrl":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-content\/uploads\/LA.png","keywords":["health policy","hepatitis C","Louisiana","medicaid","Prescription Drug Pricing","subscription model"],"articleSection":["Health Care Spending","Healthcare Delivery &amp; Payment","Healthcare Policy Development"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/appliedpolicy.com\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\/","url":"https:\/\/appliedpolicy.com\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\/","name":"Louisiana's Innovative Subscription Model Contract to Provide Hepatitis C Drugs to the State's Underserved Populations - Applied Policy","isPartOf":{"@id":"https:\/\/appliedpolicy.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/appliedpolicy.com\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\/#primaryimage"},"image":{"@id":"https:\/\/appliedpolicy.com\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\/#primaryimage"},"thumbnailUrl":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-content\/uploads\/LA.png","datePublished":"2019-04-02T14:56:05+00:00","dateModified":"2019-04-10T15:00:13+00:00","author":{"@id":"https:\/\/appliedpolicy.com\/#\/schema\/person\/a200caa45751a466fa9e77c10844020b"},"breadcrumb":{"@id":"https:\/\/appliedpolicy.com\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/appliedpolicy.com\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/appliedpolicy.com\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\/#primaryimage","url":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-content\/uploads\/LA.png","contentUrl":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-content\/uploads\/LA.png","width":200,"height":200},{"@type":"BreadcrumbList","@id":"https:\/\/appliedpolicy.com\/louisianas-innovative-subscription-model-contract-to-provide-hepatitis-c-drugs-to-the-states-underserved-populations\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/appliedpolicy.com\/"},{"@type":"ListItem","position":2,"name":"Louisiana&#8217;s Innovative Subscription Model Contract to Provide Hepatitis C Drugs to the State&#8217;s Underserved Populations"}]},{"@type":"WebSite","@id":"https:\/\/appliedpolicy.com\/#website","url":"https:\/\/appliedpolicy.com\/","name":"Applied Policy","description":"Health policy and reimbursement consulting","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/appliedpolicy.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/appliedpolicy.com\/#\/schema\/person\/a200caa45751a466fa9e77c10844020b","name":"Jim Scott","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-content\/uploads\/Scott_Jim-031-300x300.jpg","url":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-content\/uploads\/Scott_Jim-031-300x300.jpg","contentUrl":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-content\/uploads\/Scott_Jim-031-300x300.jpg","caption":"Jim Scott"},"description":"PRESIDENT &amp; CEO","url":"https:\/\/www.appliedpolicy.com\/staging\/7403\/author\/jim-scott\/"}]}},"_links":{"self":[{"href":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-json\/wp\/v2\/posts\/5106","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-json\/wp\/v2\/comments?post=5106"}],"version-history":[{"count":6,"href":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-json\/wp\/v2\/posts\/5106\/revisions"}],"predecessor-version":[{"id":5114,"href":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-json\/wp\/v2\/posts\/5106\/revisions\/5114"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-json\/wp\/v2\/media\/5107"}],"wp:attachment":[{"href":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-json\/wp\/v2\/media?parent=5106"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-json\/wp\/v2\/categories?post=5106"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.appliedpolicy.com\/staging\/7403\/wp-json\/wp\/v2\/tags?post=5106"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}